Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

Onset Dermatologics, a leader in developing and commercializing prescription products for improving skin health, today announced the launch of a 75mg strength of MINOCIN® (minocycline hydrochloride) Pellet-Filled Capsules. MINOCIN® is a tetracycline class antibiotic medicine used to treat infections caused by bacteria. MINOCIN® may be used along with other agents in the treatment of severe acne.

"MINOCIN® 75mg offers dermatologists an option for an additional strength that will complement the 50mg and 100mg strengths currently available," said Robert Moccia, President, Onset Dermatologics and CEO, Precision Dermatology. "With three strengths of MINOCIN®, dermatology practitioners are able to tailor therapy with the original minocycline to meet the needs of many patients."

"Minocycline is a second generation tetracycline commonly used in acne because of its efficacy and ease in dosing. Minocycline is effective in the treatment of acne because it has high tissue penetration, related to the molecule's affinity for lipids such as sebum. Minocycline is readily absorbed whether taken with or without food," said Dr. Neal Bhatia, Associate Professor of Dermatology at Harbor UCLA. "The option of three different strengths of MINOCIN® enables dermatologists to individualize treatment regimens, balancing efficacy and the potential for adverse events."

Source:

Onset Dermatologics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New pathway discovery explains MRSA's high-level antibiotic resistance